MOTIVE-AF: Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients (clinicaltrials.gov) - Oct 28, 2026 - P=N/A | N=700 | Not yet recruiting | Sponsor: Beijing Anzhen Hospital
Head-to-Head • New trial • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Obesity
|